Administrative Core
Administrative Core
批准号:
10526301
负责人:
Timothy An-thy Chan
金额:
$9.33万
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
未结题
起止时间:
2022-09-14 至 2027-07-31
关键词:
AccountingAnimal ExperimentationAnimalsCancer CenterClinicClinicalClinical DataClinical ManagementClinical TrialsCollaborationsCombined Modality TherapyCommunicationComprehensive Cancer CenterCore FacilityDevelopment PlansDocumentationEnrollmentEnsureFeedbackFloridaFundingGenomicsGoalsGrantHumanHuman ResourcesHuman Subject ResearchIndividualInstitutionInvestigationLaboratoriesLeadershipManuscriptsMonitorMulticenter TrialsNational Cancer InstituteOffice of Administrative ManagementOralPerformancePreparationProgress ReportsRadiationResearchResearch PersonnelResourcesScheduleServicesSiteStudy SubjectSystemTimeTrainingTreatment EfficacyUniversitiesWorkbaseexperiencehuman subjectinnovationmeetingsoperationprograms
中文摘要
项目总结
管理核心
行政核心负责全面领导、管理和执行
罗宾中心,它将提供全面的组织、行政、科学和临床管理。这个
管理核心将监督和协调所有Robin计划组件,并集中监控和
评估他们的表现。此外,行政核心将促进与外部的所有互动
咨询委员会(EAB)、指导委员会和国家知更鸟计划的其他地点。这
罗宾中心涉及3个机构(克利夫兰诊所、埃默里大学和凯斯西储医院
大学),拥有多个注册地点(克利夫兰诊所系统、克利夫兰诊所佛罗里达系统、埃默里
大学系统)跨2个NCI指定的综合癌症中心(病例综合癌症
埃默里癌症中心),代表这些机构作为项目和核心领导人。这个
行政核心人员将由Chan、Yu和Scott博士领导,并与试验和
项目负责人。陈博士和余博士(私家侦探)在管理多间院校方面均有丰富经验。
临床试验和实验室研究计划。行政核心的具体目标如下
下面是。在目标1中,核心将提供所有组织、行政、教育和科学
通过培养和提升罗宾团队,协调罗宾中心的项目和核心
创新和卓越、协作、利用资源和提供建设性反馈。
在目标2中,核心将为Robin的所有财务方面提供集中的行政管理
中心,包括但不限于临床试验执行、赠款资金核算、进展报告、
沟通、会议安排和会议记录,以及稿件和赠款的准备。《目标3》中的核心
将通过口头和书面文件评估研究进展,并定期得到EAB的投入,
指导委员会和国家癌症研究所(NCI)的领导,以确保每个项目都符合其
在建议的时间范围内实现目标,并促进与其他Robin站点的互动
居中项目。在目标4中,核心将确保跨Robin组件的整合,包括项目和
核心,跨越所有地点,并通过科学交流提供互动,协调年度科学
务虚会,并通过培训和发展计划确保最先进的做法。在目标5中,
CORE将确保和监测所有罗宾中心的人类受试者和动物研究的最佳实践
项目和核心以及临床和数据业务,并确保足够的人和动物
适用于所有项目的生物制品(以翻译和临床相关为核心)。
英文摘要
PROJECT SUMMARY
Administrative Core
The Administrative Core is responsible for the overall leadership, management, and execution of the
ROBIN center, and it will provide overall organizational, administrative, scientific and clinical management. The
Administrative Core will oversee and coordinate all ROBIN program components and centrally monitor and
evaluate their performance. In addition, the Administrative Core will facilitate all interactions with the External
Advisory Board (EAB), the Steering Committee, and the other sites of the national ROBIN program. This
ROBIN center involves 3 institutions (Cleveland Clinic, Emory University, and Case Western Reserve
University), with multiple enrollment sites (Cleveland Clinic system, Cleveland Clinic Florida system, Emory
University system) across 2 NCI-designated Comprehensive Cancer Centers (Case Comprehensive Cancer
Center, Emory Cancer Center), with representation across these institutions as project and core leaders. The
Administrative Core personnel will be led by Drs. Chan, Yu, and Scott, with collaboration from the trial and
project leads. Both Drs. Chan and Yu (ROBIN PIs) have extensive experience in managing multi-institution
clinical trial and laboratory-based research programs. The specific aims for the Administrative Core are as
follows. In Aim 1, the Core will provide all organizational, administrative, educational, and scientific
coordination for the ROBIN center projects and cores by cultivating and promoting the ROBIN team through
innovation and excellence, collaboration, leveraging resources, and providing constructive feedback.
In Aim 2, the Core will provide centralized administrative management for all fiscal aspects of the ROBIN
center, including but not limited to clinical trial execution, accounting of grant funds, progress reports,
communication, meeting scheduling and minutes, and manuscript and grant preparation. In Aim 3, the Core
will evaluate research progress through oral and written documentation, with regular input from the EAB,
Steering Committee, and National Cancer Institute (NCI) leadership to ensure that each project meets its
objectives within the proposed time frame and to facilitate interactions with other ROBIN sites for trans-ROBIN
center projects. In Aim 4, the Core will ensure integration across ROBIN components, including projects and
cores, across all sites, and provide interaction through scientific exchanges, coordination of an annual scientific
retreat, and through training and development plans that will ensure state-of-the-art practices. In Aim 5, the
Core will ensure and monitor best practices for human subjects and animal research for all ROBIN center
projects and cores as well as clinical and data operations, and to ensure adequate human and animal
biospecimens for all projects (with the Translational and Clinical Correlates Core).
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Genomic and Microenvironmental Determinants, Temporal Dynamics, and Treatment Efficacy of Radiation-Based Combination Therapies
-
批准号:10746700
-
项目类别:
-
资助金额:$3.7万
-
财政年份:2023
-
负责人:Timothy An-thy Chan
-
依托单位:
Project 3 Molecular Mechanisms Underlying Therapy Response to Radiation and Immune Checkpoint Blockade
-
批准号:10818969
-
项目类别:
-
资助金额:$6.66万
-
财政年份:2022
-
负责人:Timothy An-thy Chan
-
依托单位:
Administrative Core
-
批准号:10916639
-
项目类别:
-
资助金额:$7.09万
-
财政年份:2022
-
负责人:Timothy An-thy Chan
-
依托单位:
Administrative Core
-
批准号:10916640
-
项目类别:
-
资助金额:$6.66万
-
财政年份:2022
-
负责人:Timothy An-thy Chan
-
依托单位:
Genomic and Microenvironmental Determinants, Temporal Dynamics, and Treatment Efficacy of Radiation-Based Combination Therapies
-
批准号:10875876
-
项目类别:
-
资助金额:$7.09万
-
财政年份:2022
-
负责人:Timothy An-thy Chan
-
依托单位:
Genomic and Microenvironmental Determinants, Temporal Dynamics, and Treatment Efficacy of Radiation-Based Combination Therapies
-
批准号:10704661
-
项目类别:
-
资助金额:$147.36万
-
财政年份:2022
-
负责人:Timothy An-thy Chan
-
依托单位:
Genomic and Microenvironmental Determinants, Temporal Dynamics, and Treatment Efficacy of Radiation-Based Combination Therapies
-
批准号:10526300
-
项目类别:
-
资助金额:$156.62万
-
财政年份:2022
-
负责人:Timothy An-thy Chan
-
依托单位:
Project 1 Genetic and Immunologic Mechanisms Underlying Combination Sacituzumab plus Radiation Therapy for Bladder Cancer
-
批准号:10704713
-
项目类别:
-
资助金额:$16.46万
-
财政年份:2022
-
负责人:Timothy An-thy Chan
-
依托单位:
Project 1 Genetic and Immunologic Mechanisms Underlying Combination Sacituzumab plus Radiation Therapy for Bladder Cancer
-
批准号:10526303
-
项目类别:
-
资助金额:$19.32万
-
财政年份:2022
-
负责人:Timothy An-thy Chan
-
依托单位:
Administrative Core
-
批准号:10704708
-
项目类别:
-
资助金额:$24.74万
-
财政年份:2022
-
负责人:Timothy An-thy Chan
-
依托单位:
Pre-exposure Immunologic Health and Linkages to SARS-COV2 Serologic Responses, Endothelial Cell Resilience, and Cardiovascular Complications: Defining the mechanistic basis of high risk endotypes.
-
批准号:10680625
-
项目类别:
-
资助金额:$67.37万
-
财政年份:2020
-
负责人:Timothy An-thy Chan
-
依托单位:
Pre-exposure Immunologic Health and Linkages to SARS-COV2 Serologic Responses, Endothelial Cell Resilience, and Cardiovascular Complications: Defining the mechanistic basis of high risk endotypes.
-
批准号:10222085
-
项目类别:
-
资助金额:$135.88万
-
财政年份:2020
-
负责人:Timothy An-thy Chan
-
依托单位:
Towards Precision Immuno-Oncology: Unraveling the Genomic Determinants and Mechanisms Underlying Immunotherapy Efficacy and Resistance
-
批准号:10474453
-
项目类别:
-
资助金额:$99.2万
-
财政年份:2020
-
负责人:Timothy An-thy Chan
-
依托单位:
Pre-exposure Immunologic Health and Linkages to SARS-COV2 Serologic Responses, Endothelial Cell Resilience, and Cardiovascular Complications: Defining the mechanistic basis of high risk endotypes.
-
批准号:10706727
-
项目类别:
-
资助金额:$11.71万
-
财政年份:2020
-
负责人:Timothy An-thy Chan
-
依托单位:
TOWARDS PRECISION IMMUNO-ONCOLOGY: UNRAVELING THE GENOMIC DETERMINANTS AND MECHANISMS UNDERLYING IMMUNOTHERAPY EFFICACY AND RESISTANCE
-
批准号:10201107
-
项目类别:
-
资助金额:$16.1万
-
财政年份:2020
-
负责人:Timothy An-thy Chan
-
依托单位:
Pre-exposure Immunologic Health and Linkages to SARS-COV2 Serologic Responses, Endothelial Cell Resilience, and Cardiovascular Complications: Defining the mechanistic basis of high risk endotypes.
-
批准号:10855043
-
项目类别:
-
资助金额:$80.69万
-
财政年份:2020
-
负责人:Timothy An-thy Chan
-
依托单位:
Elucidating and targeting the molecular foundations of IDH Mutant glioma
-
批准号:10168250
-
项目类别:
-
资助金额:$7.49万
-
财政年份:2020
-
负责人:Timothy An-thy Chan
-
依托单位:
Towards Precision Immuno-Oncology: Unraveling the Genomic Determinants and Mechanisms Underlying Immunotherapy Efficacy and Resistance
-
批准号:10252073
-
项目类别:
-
资助金额:$103.33万
-
财政年份:2020
-
负责人:Timothy An-thy Chan
-
依托单位:
Towards Precision Immuno-Oncology: Unraveling the Genomic Determinants and Mechanisms Underlying Immunotherapy Efficacy and Resistance
-
批准号:10682519
-
项目类别:
-
资助金额:$99.2万
-
财政年份:2020
-
负责人:Timothy An-thy Chan
-
依托单位:
Towards Precision Immuno-Oncology: Unraveling the Genomic Determinants and Mechanisms Underlying Immunotherapy Efficacy and Resistance
-
批准号:10264128
-
项目类别:
-
资助金额:$86.57万
-
财政年份:2020
-
负责人:Timothy An-thy Chan
-
依托单位:
海外基金